Try our Advanced Search for more refined results

Expert Analysis

Conflicting Post-Bilski Cases: Classen And CyberSource

Law360, New York (September 15, 2011, 1:48 PM EDT) -- What methods cannot be patented, even if they are novel and useful? A deeply divided Federal Circuit panel struggled with that question in Classen Immunotherapies Inc. v. Biogen Idec, No. 2006-1634 (Aug. 31, 2011). Classen reveals that the Federal Circuit remains split on method patents after the U.S. Supreme Court's decision in Bilski v. Kappos, 130 S. Ct. 3218 (2010)....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Companies

Government Agencies

Judge Analytics

powered by Lex Machina®

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!